<DOC>
	<DOCNO>NCT00567034</DOCNO>
	<brief_summary>The main purpose study determine whether opioid antagonist naltrexone helpful ameliorate weight gain adverse metabolic side effect experience schizophrenic patient take second generation antipsychotic ( SGA ) Zyprexa . Schizophrenics may altered/enhanced endogenous opioidergic drive , , normally painful stimulus sense less painful schizophrenic vs. healthy control . A secondary hypothesis study naltrexone augmentation Zyprexa normalize subjective pain rating . Our tertiary objective examine safety tolerability naltrexone Zyprexa-treated patient schizophrenia .</brief_summary>
	<brief_title>Augmenting Zyprexa With Naltrexone Ameliorate Metabolic Side-Effects</brief_title>
	<detailed_description>Zyprexa one commonly prescribed second generation antipsychotic drug ( SGAs ) , ( SGA 's ) side effect contribute development obesity `` Metabolic Syndrome . '' Both condition , prevalent even unmedicated schizophrenic patient , associate increase cardiovascular morbidity mortality . The mechanisms side effect likely multifactorial involve peripheral central factor alike . The present proposal ask fundamental question : How endogenous opioidergic system involve Zyprexa-induced obesity relate metabolic disturbance . We hypothesize excess central opioid activity create metabolic problem patient , reasonable expect amelioration symptom blockade opioid receptor . The propose project design test hypothesis compliment clinical psychopharmacology pain medicine research functional magnetic resonance imaging ( fMRI ) empirically measure clinical outcome Zyprexa pharmacotherapy augmentation opioid receptor antagonist , naltrexone . Our objective hypotheses follow : determine effect naltrexone weight gain , metabolic ( e.g. , cholesterol , lipid , insulin , leptin glucose level ) , anthropometric nutritional characteristic Zyprexa treat schizophrenic patient , examine effect naltrexone subjective pain rating , investigate safety tolerability naltrexone Zyprexa-treated schizophrenic patient .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Meeting DSMIVTR criterion schizophrenia/schizoaffective disorder , confirm clinical interview PI SCIDI . On stable dose Zyprexa ( i.e. , great equal 10mg/day less equal 30mg/day ) least 2 month ; patient typical antipsychotic medicationsfree state also include used baseline comparison . Sufficient clinical stability ( i.e. , BPRS psychotic symptom score less 19 ; BPRS anxiety/depression symptom score less 15 ) . Participation approve treat psychiatrist . BMI great equal 30kg/m^2 BMI great equal 27kg/m^2 plus one symptom `` Metabolic Syndrome '' ( i.e. , fast blood sugar great 125mg/dL , hypertension dyslipidemia ) . Sufficient social stability follow study admission , safe , reliable living quarter , telephone access least one live relative significant willing assist subject follow discharge study assist staff necessary locate subject subsequently . English speak read ability sufficient comprehend consent without assistance . Good physical health , history significant medical , surgical , neurological illness , include history head trauma . Righthandedness Able cooperate comply study procedure . DSMIVTR diagnosis current drug/alcohol dependence . Any lifetime history dementia , bipolar disorder , major depression , psychotic disorder , past current drug/alcohol dependence , past current eating disorder . Potentially confound neurological condition ( e.g. , seizure disorder , head trauma accompany loss consciousness great ten minute amnesia , brain surgery , multiple sclerosis , Parkinson 's disease ) , potentially confound medical condition ( e.g. , diabetes mellitus endocrinopathy , chronic obstructive pulmonary disease , congestive heart failure , hepatitis , hepatic failure cirrhosis , AIDS , pacemaker , kidney problem , hypokalemia , edema , allergy glucose ) . Allergy hypersensitivity naltrexone Abnormal laboratory , ECG EEG result , elevate serum aminotransferase . Use within previous month potentially confound medication opioid agonist ( e.g. , morphine codeine ) drug prominent orexigenic/anorexigenic effect ( e.g. , anticholinergic ) , insulin , oral hypoglycemics , amphetamine , opioid analgesic , antidepressant include tricyclic , MAO inhibitor mirtazapine , determine history and/or urine toxicology screen . Patient pregnant plan become pregnant . Any cognitive impairment precludes informed consent . Any chronic pain condition and/or condition may require opioid treatment course study . Dangerousness : suicidal , assaultive homicidal risk</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Zyprexa</keyword>
	<keyword>naltrexone</keyword>
	<keyword>schizophrenia</keyword>
	<keyword>Metabolic Syndrome</keyword>
	<keyword>pain</keyword>
</DOC>